KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Shares Outstanding (Weighted Average) (2017 - 2025)

Amneal Pharmaceuticals (AMRX) has 9 years of Shares Outstanding (Weighted Average) data on record, last reported at $313.4 million in Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 1.42% year-over-year to $313.4 million; the TTM value through Dec 2025 reached $313.4 million, up 1.42%, while the annual FY2025 figure was $313.4 million, 1.42% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $313.4 million in Q4 2025 per AMRX's latest filing, roughly flat from $313.0 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $313.4 million in Q4 2025 and bottomed at $148.0 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $215.8 million, with a median of $154.0 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Weighted Average): increased 0.57% in 2021, then skyrocketed 102.01% in 2024.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $148.9 million in 2021, then rose by 1.36% to $150.9 million in 2022, then rose by 16.69% to $176.1 million in 2023, then surged by 75.42% to $309.0 million in 2024, then increased by 1.42% to $313.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Weighted Average) were $313.4 million in Q4 2025, $313.0 million in Q3 2025, and $312.4 million in Q2 2025.